The clinical phase of Ziprasidone study was executed from 08th June 2011 to 04th July 2011.
The bioanalytical method for the analysis of clinical phase study samples was developed based on the available literature. Literature mentioned about using liquid-liquid extraction for sample preparation and LC-MS/MS method for analysis.
The developed method was validated based upon method validation protocol, BEQ-VP-ZIP-293/01 which was effective from 14th July 2011.
The method validation was carried out from 15th July 2011 to 26th July 2011; the data generated was audited by the Quality Assurance department. The method validation report BEQ/VR/ZIP-293/01 and the Standard Test Procedure i.e. STP (BEQ/AL/STP-293/01) were released on 27th July 2011.
The analysis of the clinical study samples was done from 30th July 2011 to 08th August 2011 using the above mentioned validated bioanalytical method. Thus, the accuracy of the concentrations obtained from the analysis of clinical study samples has not been compromised.